2 reports of this reaction
2.9% of all SILICEA reports
#3 most reported adverse reaction
MULTIPLE SCLEROSIS RELAPSE is the #3 most commonly reported adverse reaction for SILICEA, manufactured by BM Private Limited. There are 2 FDA adverse event reports linking SILICEA to MULTIPLE SCLEROSIS RELAPSE. This represents approximately 2.9% of all 70 adverse event reports for this drug.
Patients taking SILICEA who experience multiple sclerosis relapse should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
MULTIPLE SCLEROSIS RELAPSE is a less commonly reported adverse event for SILICEA, but still significant enough to appear in the safety profile.
In addition to multiple sclerosis relapse, the following adverse reactions have been reported for SILICEA:
The following drugs have also been linked to multiple sclerosis relapse in FDA adverse event reports:
MULTIPLE SCLEROSIS RELAPSE has been reported as an adverse event in 2 FDA reports for SILICEA. This does not prove causation, but indicates an association observed in post-market surveillance data.
MULTIPLE SCLEROSIS RELAPSE accounts for approximately 2.9% of all adverse event reports for SILICEA, making it one of the most commonly reported side effect.
If you experience multiple sclerosis relapse while taking SILICEA, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.